DENVER, April 18, 2016 -- BioScrip, Inc. (NASDAQ:BIOS) announced today that the Company will release its 2015 first quarter financial results on Thursday, May 5, 2016, after the close of the U.S. financial markets.
Richard M. Smith, President and Chief Executive Officer, and Jeffrey M. Kreger, Senior Vice President, Chief Financial Officer and Treasurer, will conduct a conference call as follows:
| Date | Friday, May 6, 2016 | ||
| Time | 8:00 a.m. EDT | ||
| Toll free (U.S.) | (888) 372-9592 | ||
| International | (918) 559-5628 | ||
| Webcast (live and replay) | www.bioscrip.com | ||
A replay of the conference call will be available for one week after the call's completion by dialing (855) 859-2056 (US) or (404) 537-3406 (International) and entering conference call ID number 94119366. An audio webcast and archive will also be available for 30 days under the "Investor Relations" section of the BioScrip website at www.bioscrip.com.
About BioScrip, Inc.
BioScrip, Inc. is a leading national provider of infusion and home healthcare management solutions. BioScrip partners with healthcare providers, including physicians, hospital systems, skilled nursing facilities, and with healthcare payors to provide patients better access to high quality, efficient post-acute care services. BioScrip operates with a commitment to bring infusion therapy services into the home or alternate-site settings. By collaborating with the full spectrum of healthcare professionals and the patient, BioScrip provides cost-effective care that is driven by clinical excellence, customer service, and values that promote positive outcomes and an enhanced quality of life for those it serves.
Contact: Lisa Wilson In-Site Communications, Inc. T: 212-452-2793 E: [email protected]


Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
Italy Fines Apple €98.6 Million Over App Store Dominance
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 



